PPeak Bggradded this to Biotech InvestingFDA FDA rejects AstraZeneca application for expanded use of FarxigaSeeking Alpha - Douglas W. House AstraZeneca (NYSE:AZN) announces that it received a CRL from the FDA in response to its supplemental marketing application seeking approval for …
Macclesfield A display of sensitivitynature.com - www.nature.com Scientific progress often relies on applying published methodological advances to different problems. With the aim of improving both the uptake and …
Investing.com Indiaadded this to India NewsU.S. Food and Drug Administration UPDATE 1-UK Stocks-Factors to watch on July 15investing.com July 15 (Reuters) - Britain's futures .FFIc1 is seen opening up 0.01% on Monday, with futures FFIc1 up 0.02% ahead of the cash market open. * SPORTS …
ReutersUnited Kingdom PRESS DIGEST- British Business - July 15Reuters - Reuters EditorialJuly 15 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy. - Britain's Labour party
Reutersadded this to Health & LifestyleOvarian Cancer GSK drug helps ovarian cancer patients live longer in late-stage studyReuters - By Noor Zainab Hussain and Pushkala Aripaka(Reuters) - GlaxoSmithKline Plc's cancer treatment Zejula met the main goal of helping patients with ovarian cancer live longer without their disease worsening in a late-stage study, the company said Monday.
Mariam Emadadded this to Intriguing Medicine Ovarian Cancer GSK’s ovarian cancer drug shows ‘exciting’ resultscityam.com - Joe Curtis British pharmaceuticals giant Glaxosmithkline reported progress this morning on a drug it bought last year in a controversial $5.1bn (£4bn) …
The Evening Standardadded this to Business | Evening StandardCancer Comment: Glaxo's risks may bear fruit with cancer treatment hopesstandard.co.uk - JIM ARMITAGE Since becoming GlaxoSmithKline CEO last year, Emma Walmsley has swept through it like a tornado. Within months, she’d done a £10bn joint venture deal …
Sky Newsadded this to UK NewsGlaxoSmithKline GSK turns to former AstraZeneca exec to lead £80bn break-upsky.com - By Mark Kleinman Jonathan Symonds has been picked to succeed Sir Philip Hampton as GlaxoSmithKline's chairman, Sky News learns. Britain's second-biggest drug-maker is …
TheStreetadded this to Jim Cramer Jim Cramer Jim Cramer: Here's How Investors Should React to Market HighsTheStreet - Katherine Ross Jim Cramer tackles the market highs and how investors should react to them, Trump's tweets about Facebook's Libra, and what investors should watch …
Merck AstraZeneca's Imfinzi Gains Orphan Drug Status for SCLCyahoo.com - Zacks Equity Research AstraZeneca PLC AZN announced that the FDA has granted an orphan drug designation to its PD-L1 inhibitor, Imfinzi (durvalumab), for the treatment of …
MarketWatchadded this to BusinessU.S. Food and Drug Administration AstraZeneca cancer drug gets U.S. orphan statusMarketWatch - By Carlo Martuscelli AstraZeneca PLC (AZN.LN) said Friday that the U.S. Food and Drug Administration had awarded its cancer drug Imfinzi orphan drug status as a treatment …
Why one top exec at this $105 billion drugmaker is 'very disappointed' with Trumpyahoo.com - Brian Sozzi It’s been a mixed week for the health care space indeed. After months of behind the scenes political posturing, the Trump administration walked back …
Seeking AlphaLung Cancer AstraZeneca's Imfinzi an Orphan drug in U.S. for lung cancerSeeking Alpha - Mamta Mayani The FDA has granted Orphan Drug Designation (ODD) to AstraZeneca's (NYSE:AZN) Imfinzi (durvalumab) for the treatment of small cell lung cancer (SCLC). …
TheStreetadded this to InvestingTech Industry Snap Spikes as Goldman Sachs Predicts OutperformanceTheStreet - Tony Owusu The Dow Jones Industrial Average and the S&P 500 open Friday at new intraday highs. The three either have made recent progress toward advancing …
FDA Pharma Stock Roundup: Pipeline & Regulatory Updates by MRK, GSK, SNYyahoo.com - Kinjel Shah This week was relatively quiet for the pharma sector ahead of a string of earnings releases toward the end of this month. Glaxo GSK provided pipeline …
The Evening Standardadded this to Business | Evening StandardBoeing Market report: Boeing turbulence fuels fears over bumpy flight for supplier Seniorstandard.co.uk - Mark Shapland Engineering firm Senior has its results out next month and today brokers told investors to brace themselves for ugly figures. The FTSE 250 firm …
TheStreetPharma AstraZeneca Biopharma President Talks Drug Rebates, PricingTheStreet - Kevin Curran The government's decision to drop its plan to cut drug rebates from government drug plans could be a negative factor for pharma, according to …
Seeking AlphaInvesting Big Biopharma in the red as investors wait for Trump's drug price planSeeking Alpha - Douglas W. House Major drug makers are under water nearing the close as skittish investors move the sidelines ahead of President Trump's plan to peg Medicare …
Investor's Business Dailyadded this to Financial & Business NewsBusiness AstraZeneca Earns IBD Rating Upgradeinvestors.com - INVESTOR'S BUSINESS DAILY In a welcome move, AstraZeneca (AZN) saw its Relative Strength Rating improve from 68 to 72 on Wednesday. X When looking for the best stocks to buy and …
VentureBeatU.S. Dept. of Veterans Affairs Vyopta Secures $7.5 Million in Series B Funding from Elsewhere Partners to Optimize Workplace CollaborationVentureBeat - Business WireCompany to Use Funds to Accelerate Market Penetration, Product Innovation and Leadership in Collaboration Monitoring and Analytics Vyopta, the leading developer of monitoring and analytics tools to optimize
FlipboardIcon version of the Flipboard logoLaw Third Circuit Dismisses FCA Case Under Pre-ACA Version of Public Disclosure Barnatlawreview.com - Mintz Jane HavilandJurisdiction: 3rd Circuit (incl. bankruptcy)Type of Law: Health Law & Managed CareCriminal Law / Business CrimesLitigation / Trial …
Miss Maryadded this to MissMary Finance Here's how you can find the prices of some popular drugs onlineyahoo.com - Alexis Keenan and Anjalee Khemlani A federal district court judge on Monday stopped the Trump administration from requiring drug makers to disclose drug wholesale prices in TV ads. Had …
PPeak Bggradded this to Biotech InvestingJohnson & Johnson Drug makers perk up on block of price disclosures in TV adsSeeking Alpha - Douglas W. House Biotechs and biopharma players are modestly in the green after a D.C. district court stopped a Trump administration initiative requiring drug makers …
Forbesadded this to TechnologyVenture Capital Baroness Joanna Shields' BenevolentAI Is Reportedly Preparing To Slash Its $2 Billion ValuationForbes - Sam SheadBenevolentAI, a buzzy London tech startup trying to discover new drugs with artificial intelligence, is lowering its valuation, according to a report from The Times. Led by Baroness Joanna Shields, the
Bloombergadded this to Asia NewsUnited States European Drug Stocks Hit, Even as Trump Price Plan Seen as NoiseBloomberg - Joe Easton Health care was the worst-performing sector in European stocks Monday after Donald Trump hinted at his latest plan to cut drug prices in the U.S., …
The Telegraphadded this to BusinessLung Cancer AstraZeneca boss calls for NHS drug approval shake-upThe Telegraph - By Julia BradshawAstraZeneca has called for a wholesale review of the way new drugs are paid for in England and Wales after Nice refused to pay for one of its most important cancer medications. Nice, the government body
Investor's Business Dailyadded this to Financial & Business NewsBusiness Stocks Generating Improved Relative Strength: Grifolsinvestors.com - INVESTOR'S BUSINESS DAILY Grifols (GRFS) saw a positive improvement to its Relative Strength (RS) Rating on Friday, rising from 61 to 71. X When looking for the best stocks to …
Bloombergadded this to Bloomberg TelevisionCEOs How AstraZeneca's CEO Doubled the Company's Share PriceBloomberg AstraZeneca Plc Chief Executive Officer Pascal Soriot has shifted the company's focus back to developing medicine, and in the process revitalized its …
Investor's Business Dailyadded this to Financial & Business NewsFlipboardIcon version of the Flipboard logoBusiness AstraZeneca Earns Technical Rating Upgradeinvestors.com - INVESTOR'S BUSINESS DAILY AstraZeneca (AZN) saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 69 to 72. X When looking for the best …
IKITOadded this to Healthy LivingFlipboardIcon version of the Flipboard logoMetabolism First time human-on-a-chip predicts in vivo results based on in vitro model | EurekAlert! Science Newseurekalert.org Hesperos' integrated heart-liver Human-on-a-Chip® shown to correctly determine cardiotoxic mechanisms pre-clinically and replicate results seen in in …
